Nippon Chemiphar Sees Profits Halved
Sales Drop 4% Due To Japanese NHI Drug Price Revisions
Japanese NHI drug price revisions implemented in October 2019 are responsible for operating profits halving amid declining sales and future uncertainty, Nippon Chemiphar said as it slashed its full-year forecast.
